Tectonic Therapeutic (TECX) to Release Quarterly Earnings on Thursday

Tectonic Therapeutic (NASDAQ:TECX) is anticipated to issue its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Tectonic Therapeutic to post earnings of ($1.10) per share for the quarter.

Tectonic Therapeutic (NASDAQ:TECX) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($1.39) by $0.55. On average, analysts expect Tectonic Therapeutic to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Tectonic Therapeutic Price Performance

Shares of NASDAQ:TECX opened at $21.39 on Tuesday. The company has a market capitalization of $399.37 million, a PE ratio of -3.63 and a beta of 3.44. Tectonic Therapeutic has a 1 year low of $13.70 and a 1 year high of $61.07. The business has a fifty day moving average price of $20.06 and a two-hundred day moving average price of $34.71.

Insiders Place Their Bets

In related news, CFO Daniel Lochner acquired 4,617 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were bought at an average cost of $54.14 per share, for a total transaction of $249,964.38. Following the purchase, the chief financial officer now owns 4,617 shares in the company, valued at $249,964.38. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Timothy A. Springer bought 3,718 shares of the business’s stock in a transaction on Wednesday, April 9th. The stock was bought at an average price of $14.76 per share, with a total value of $54,877.68. Following the purchase, the director now owns 4,317,276 shares in the company, valued at $63,722,993.76. This trade represents a 0.09 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 234,607 shares of company stock worth $8,955,655 over the last quarter. 9.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have commented on TECX shares. Mizuho initiated coverage on shares of Tectonic Therapeutic in a research report on Monday, April 21st. They issued an “outperform” rating and a $51.00 price objective on the stock. Wells Fargo & Company decreased their price target on shares of Tectonic Therapeutic from $112.00 to $101.00 and set an “overweight” rating for the company in a research note on Friday, March 21st. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $72.40.

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.